STDY - SteadyMed Stock Price, News & Analysis

$3.05 -0.05 (-1.61 %)
(As of 11/23/2017 04:00 PM ET)
Previous Close$3.10
Today's Range$3.01 - $3.10
52-Week Range$2.25 - $9.70
Volume3,800 shs
Average Volume68,016 shs
Market Capitalization$82.32 million
P/E RatioN/A
Dividend YieldN/A
Beta0.89

About SteadyMed (NASDAQ:STDY)

SteadyMed logoSteadyMed Ltd. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of various therapeutic product candidates. Its primary focus is to obtain approval in the United States for the sale of Trevyent for the treatment of pulmonary arterial hypertension (PAH). It is also developing approximately two products for the treatment of post-surgical and acute pain in the home setting, which include bupivacaine PatchPump for local anesthesia post-surgery and ketorolac PatchPump for short-term management of moderately severe acute pain. Its product candidates are enabled by its PatchPump. Its Trevyent offers a way of administration of treprostinil for subcutaneous or intravenous treatment of PAH patients. The Company's ketorolac At Home Patient Analgesia (AHPA) product candidate is used for the short-term (approximately five days) management of moderately severe acute pain that requires analgesia at the opioid level in a post-surgical setting.


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:STDY
CUSIPN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio10.47%
Quick Ratio10.47%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.07 million
Price / Sales75.71
Cash FlowN/A
Price / CashN/A
Book Value$1.11 per share
Price / Book2.75

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($1.39)
Net Income$-25,860,000.00
Net Margins-1,542.71%
Return on Equity-46.77%
Return on Assets-19.75%

Miscellaneous

Employees27
Outstanding Shares26,560,000

Frequently Asked Questions for SteadyMed (NASDAQ:STDY)

What is SteadyMed's stock symbol?

SteadyMed trades on the NASDAQ under the ticker symbol "STDY."

How were SteadyMed's earnings last quarter?

SteadyMed Ltd. (NASDAQ:STDY) issued its earnings results on Friday, August, 11th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.01. The business had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.26 million. SteadyMed had a negative return on equity of 46.77% and a negative net margin of 1,542.71%. View SteadyMed's Earnings History.

When will SteadyMed make its next earnings announcement?

SteadyMed is scheduled to release their next quarterly earnings announcement on Wednesday, April, 4th 2018. View Earnings Estimates for SteadyMed.

Where is SteadyMed's stock going? Where will SteadyMed's stock price be in 2017?

2 analysts have issued 1 year price targets for SteadyMed's stock. Their predictions range from $15.00 to $17.00. On average, they expect SteadyMed's stock price to reach $16.00 in the next year. View Analyst Ratings for SteadyMed.

Who are some of SteadyMed's key competitors?

Who are SteadyMed's key executives?

SteadyMed's management team includes the folowing people:

  • Keith Bank, Independent Chairman of the Board (Age 55)
  • Jonathan M N Rigby, President, Chief Executive Officer, Director (Age 47)
  • David W Nassif, Chief Financial Officer, Executive Vice President (Age 61)
  • Elizabeth A. Cermak, Director (Age 56)
  • Stephen J. Farr Ph.D., Independent Director (Age 56)
  • Ron Ginor, Independent Director
  • Donald D. Huffman, Independent Director (Age 68)
  • William S. Slattery, Independent Director (Age 54)

When did SteadyMed IPO?

(STDY) raised $56 million in an IPO on Friday, March 20th 2015. The company issued 4,300,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

Who owns SteadyMed stock?

SteadyMed's stock is owned by many different of institutional and retail investors. Top institutional investors include Susquehanna International Group LLP (0.13%). Company insiders that own SteadyMed stock include Keith Bank and Orbimed Advisors Llc. View Institutional Ownership Trends for SteadyMed.

Who sold SteadyMed stock? Who is selling SteadyMed stock?

SteadyMed's stock was sold by a variety of institutional investors in the last quarter, including Susquehanna International Group LLP. View Insider Buying and Selling for SteadyMed.

How do I buy SteadyMed stock?

Shares of SteadyMed can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is SteadyMed's stock price today?

One share of SteadyMed stock can currently be purchased for approximately $3.05.

How big of a company is SteadyMed?

SteadyMed has a market capitalization of $82.32 million and generates $1.07 million in revenue each year. The company earns $-25,860,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. SteadyMed employs 27 workers across the globe.

How can I contact SteadyMed?

SteadyMed's mailing address is 5 OPPENHEIMER STREET, REHOVOT L3, 7670105. The company can be reached via phone at 925-272-4999 or via email at [email protected]


MarketBeat Community Rating for SteadyMed (STDY)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  67 (Vote Outperform)
Underperform Votes:  40 (Vote Underperform)
Total Votes:  107
MarketBeat's community ratings are surveys of what our community members think about SteadyMed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for SteadyMed (NASDAQ:STDY)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.00 (424.59% upside)

Consensus Price Target History for SteadyMed (NASDAQ:STDY)

Price Target History for SteadyMed (NASDAQ:STDY)

Analysts' Ratings History for SteadyMed (NASDAQ:STDY)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/5/2017JMP SecuritiesReiterated RatingOutperform$11.00 -> $17.00MediumView Rating Details
4/3/2017HC WainwrightReiterated RatingBuy$10.00 -> $15.00HighView Rating Details
3/28/2016Royal Bank Of CanadaReiterated RatingBuyN/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for SteadyMed (NASDAQ:STDY)

Earnings by Quarter for SteadyMed (NASDAQ:STDY)

Earnings History by Quarter for SteadyMed (NASDAQ STDY)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/4/2018        
8/11/20176/30/2017($0.32)($0.33)$0.26 million$0.32 millionViewN/AView Earnings Details
8/15/2016Q2($0.52)($0.53)$0.09 millionViewN/AView Earnings Details
5/11/2016Q1($0.48)($0.46)$0.38 millionViewN/AView Earnings Details
3/29/2016Q4($0.45)($0.48)$0.43 millionViewN/AView Earnings Details
11/12/2015Q315($0.55)($0.44)$0.44 millionViewListenView Earnings Details
8/13/2015Q215($0.44)($0.51)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for SteadyMed (NASDAQ:STDY)
Current Year EPS Consensus Estimate: $-2.26 EPS
Next Year EPS Consensus Estimate: $-1.83 EPS

Dividends

Dividend History for SteadyMed (NASDAQ:STDY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for SteadyMed (NASDAQ STDY)

Insider Ownership Percentage: 49.75%
Institutional Ownership Percentage: 57.87%
Insider Trades by Quarter for SteadyMed (NASDAQ:STDY)
Insider Trades by Quarter for SteadyMed (NASDAQ:STDY)

Insider Trades by Quarter for SteadyMed (NASDAQ STDY)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/25/2017Orbimed Advisors LlcMajor ShareholderBuy1,174,000$5.90$6,926,600.00View SEC Filing  
8/4/2016Keith BankDirectorBuy266,257$3.13$833,384.41View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for SteadyMed (NASDAQ STDY)

Source:
DateHeadline
SteadyMed Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateSteadyMed Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 14 at 8:20 AM
SteadyMed Ltd. (STDY) Scheduled to Post Earnings on MondaySteadyMed Ltd. (STDY) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - November 6 at 6:26 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of SteadyMed Ltd. -- STDYINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of SteadyMed Ltd. -- STDY
finance.yahoo.com - November 4 at 5:49 PM
Glancy Prongay & Murray LLP Continues Investigation on Behalf of SteadyMed Ltd. Investors (STDY)Glancy Prongay & Murray LLP Continues Investigation on Behalf of SteadyMed Ltd. Investors (STDY)
finance.yahoo.com - November 2 at 9:23 AM
SteadyMed Receives Notice of Allowance for its European Patent Relating to Enhanced Reduction of Infusion-Site PainSteadyMed Receives Notice of Allowance for its European Patent Relating to Enhanced Reduction of Infusion-Site Pain
feeds.benzinga.com - October 12 at 9:25 AM
SteadyMed Submits Type A Meeting Request Package to FDASteadyMed Submits Type A Meeting Request Package to FDA
globenewswire.com - September 28 at 11:43 AM
INVESTOR ALERT: Goldberg Law PC Announces an Investigation of SteadyMed Ltd.INVESTOR ALERT: Goldberg Law PC Announces an Investigation of SteadyMed Ltd.
finance.yahoo.com - September 9 at 8:57 AM
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of SteadyMed Ltd. (STDY) InvestorsINVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of SteadyMed Ltd. (STDY) Investors
finance.yahoo.com - September 7 at 9:25 AM
Investor Alert: Kaplan Fox Announces Investigation Of SteadyMed Ltd.Investor Alert: Kaplan Fox Announces Investigation Of SteadyMed Ltd.
finance.yahoo.com - September 2 at 9:10 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SteadyMed Ltd.- STDYSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SteadyMed Ltd.- STDY
finance.yahoo.com - September 2 at 9:10 AM
Glancy Prongay & Murray LLP Commences Investigation on Behalf of SteadyMed Ltd. Investors (STDY)Glancy Prongay & Murray LLP Commences Investigation on Behalf of SteadyMed Ltd. Investors (STDY)
finance.yahoo.com - September 2 at 9:10 AM
SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of SteadyMed Ltd.SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of SteadyMed Ltd.
finance.yahoo.com - September 2 at 9:10 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SteadyMed Ltd. - STDYSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SteadyMed Ltd. - STDY
finance.yahoo.com - September 1 at 9:14 AM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of SteadyMed Ltd. (STDY)SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of SteadyMed Ltd. (STDY)
finance.yahoo.com - September 1 at 9:14 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of SteadyMed Ltd.SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of SteadyMed Ltd.
finance.yahoo.com - September 1 at 9:14 AM
STEADYMED LTD. INVESTOR ALERT: Girard Gibbs Investigates Potential Securities Law ViolationsSTEADYMED LTD. INVESTOR ALERT: Girard Gibbs Investigates Potential Securities Law Violations
finance.yahoo.com - September 1 at 9:14 AM
Corporate News Blog - FDA Grants Approval to The Medicines Co.’s VABOMERE(TM)Corporate News Blog - FDA Grants Approval to The Medicines Co.’s VABOMERE(TM)
finance.yahoo.com - September 1 at 9:14 AM
SteadyMed Ltd. (STDY) Announces Receipt of Refusal to File Letter from FDA for Trevyent NDASteadyMed Ltd. (STDY) Announces Receipt of Refusal to File Letter from FDA for Trevyent NDA
www.streetinsider.com - August 31 at 10:30 AM
SteadyMed Receives Refusal to File Letter from FDA for Trevyent® New Drug ApplicationSteadyMed Receives Refusal to File Letter from FDA for Trevyent® New Drug Application
finance.yahoo.com - August 31 at 10:30 AM
FDA Crushes SteadyMed With Refusal to File LetterFDA Crushes SteadyMed With Refusal to File Letter
finance.yahoo.com - August 31 at 10:30 AM
SteadyMed Ltd. :STDY-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017SteadyMed Ltd. :STDY-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 1:29 PM
SteadyMed Ltd. (NASDAQ:STDY) Posts  Earnings Results, Misses Expectations By $0.01 EPSSteadyMed Ltd. (NASDAQ:STDY) Posts Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - August 12 at 10:56 AM
SteadyMed Reports Second Quarter 2017 Financial Results and Provides Corporate UpdateSteadyMed Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 12 at 8:09 AM
SteadyMed Ltd. (STDY) to Release Earnings on MondaySteadyMed Ltd. (STDY) to Release Earnings on Monday
www.americanbankingnews.com - August 7 at 8:08 AM
SteadyMed Appoints Jeff Myers M.D. Ph.D. Vice President of Medical AffairsSteadyMed Appoints Jeff Myers M.D. Ph.D. Vice President of Medical Affairs
finance.yahoo.com - August 1 at 6:35 AM
Cardiome's Partner SteadyMed Submits NDA for PAH InjectionCardiome's Partner SteadyMed Submits NDA for PAH Injection
finance.yahoo.com - July 4 at 3:30 PM
SteadyMed to Present at the 2017 JMP Securities Life Sciences ConferenceSteadyMed to Present at the 2017 JMP Securities Life Sciences Conference
feeds.benzinga.com - June 13 at 8:52 AM
SteadyMed Ltd. (STDY) Raises $5M from Key Institutional ShareholderSteadyMed Ltd. (STDY) Raises $5M from Key Institutional Shareholder
www.streetinsider.com - May 27 at 6:02 AM
SteadyMed Ltd. (STDY) Announces $30M Private Placement of Ordinary Shares, WarrantsSteadyMed Ltd. (STDY) Announces $30M Private Placement of Ordinary Shares, Warrants
www.streetinsider.com - April 22 at 11:31 AM
SteadyMed Wins Patent Challenge (STDY, UTHR)SteadyMed Wins Patent Challenge (STDY, UTHR)
www.investopedia.com - April 3 at 7:47 PM
SteadyMed Wins Patent Challenge Vs United TherapeuticsSteadyMed Wins Patent Challenge Vs United Therapeutics
www.investopedia.com - April 3 at 7:47 PM
Setback For ACOR In Ampyra Suit, EARS Put On Notice, STDY On Steady RiseSetback For ACOR In Ampyra Suit, EARS Put On Notice, STDY On Steady Rise
www.nasdaq.com - April 3 at 12:49 AM
SteadyMed Ltd. (STDY) Granted Favorable Ruiling in Inter Partes Review Against United Therapeutics (UTHR) PatentSteadyMed Ltd. (STDY) Granted Favorable Ruiling in Inter Partes Review Against United Therapeutics (UTHR) Patent
www.streetinsider.com - April 2 at 11:43 AM
SteadyMed Receives Favorable Ruling in Inter Partes Review against United Therapeutics PatentSteadyMed Receives Favorable Ruling in Inter Partes Review against United Therapeutics Patent
www.nasdaq.com - March 31 at 3:19 PM
STEADYMED LTD. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsSTEADYMED LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - January 9 at 11:44 PM
8:33 am SteadyMed provides update regarding its ongoing IPR challenging a United Therapeutics (<a href="/q?s=uthr" name="uthr">UTHR</a>) patent; co expects a final decision from the PTAB in April 20178:33 am SteadyMed provides update regarding its ongoing IPR challenging a United Therapeutics (UTHR) patent; co expects a final decision from the PTAB in April 2017
us.rd.yahoo.com - December 5 at 7:46 PM
New Website Provides Expert Lifestyle Information and Personal Tips from People with PHNew Website Provides Expert Lifestyle Information and Personal Tips from People with PH
globenewswire.com - November 17 at 11:55 AM
STEADYMED LTD. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsSTEADYMED LTD. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - October 18 at 11:48 AM
STEADYMED LTD. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of MatSTEADYMED LTD. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Mat
biz.yahoo.com - October 11 at 8:26 PM
SteadyMed Ltd. (STDY) Completes Trevyent Manufacturing Requirements for NDA SubmsisionSteadyMed Ltd. (STDY) Completes Trevyent Manufacturing Requirements for NDA Submsision
www.streetinsider.com - September 1 at 10:41 AM
STEADYMED LTD. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity SecuritiesSTEADYMED LTD. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities
biz.yahoo.com - August 1 at 6:05 AM
SteadyMed Ltd. (STDY) Announces $32M Equity RaiseSteadyMed Ltd. (STDY) Announces $32M Equity Raise
www.streetinsider.com - July 31 at 11:25 AM
Antarcticas Ozone Hole Is Shrinking, Study ShowsAntarctica's Ozone Hole Is Shrinking, Study Shows
abcnews.go.com - July 2 at 10:10 AM
Study: Atheists, Christians more alike than you thinkStudy: Atheists, Christians more alike than you think
www.huffingtonpost.com - July 2 at 10:10 AM
Study: Ozone hole over Antarctica beginning to healStudy: Ozone hole over Antarctica beginning to heal
www.usatoday.com - July 2 at 10:10 AM
STEADYMED LTD. Files SEC form 10-Q, Quarterly ReportSTEADYMED LTD. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - May 11 at 10:35 AM
STEADYMED LTD. Files SEC form 10-K, Annual ReportSTEADYMED LTD. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 29 at 5:09 PM
Some ‘cheap’ biotech stocks that could be buyout targets, RBC saysSome ‘cheap’ biotech stocks that could be buyout targets, RBC says
www.marketwatch.com - January 25 at 1:31 PM
Steadymed Ltd Earnings Call scheduled for 4:30 pm ET todaySteadymed Ltd Earnings Call scheduled for 4:30 pm ET today
biz.yahoo.com - November 12 at 4:30 PM
STEADYMED LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsSTEADYMED LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - November 12 at 4:09 PM

Social Media

Financials

Chart

SteadyMed (NASDAQ STDY) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.